NIDDM is a common heterogeneous disorder, the genetic basis of which has yet to be determined. The sulfonylurea receptor (SUR) gene, now known to encode an integral component of the pancreatic P-cell ATP-sensitive potassium channel, IKATP> w a s investigated as a logical candidate for this disorder. The two nucleotide-binding fold (NBF) regions of SUR are known to be critical for normal glucose regulation of insulin secretion. Thus, singlestrand conformational polymorphism analysis was used to find sequence changes in the two NBF regions of the SUR gene in 35 NIDDM patients. Eight variants were found; and three were evaluated in two Northern European white populations (Utah and the U.K.): 1) a missense mutation in exon 7 (S1370A) was found with equal frequency in patients (n = 223) and control subjects (n = 322); 2 ) an ACf^ACT silent variant in exon 22 (T761T) was more common in patients than in control subjects (allele frequencies 0.07 vs. 0.02, P = 0.0008, odds ratio (OR) 3.01, 95% CI 1.54-5.87); and 5 ) an intronic t^c change located at position -3 of the exon 24 splice acceptor site was also more common in patients than in control subjects (0.62 vs. 0.46, P < 0.0001, OR 1.91, 95% Cl 1.50-2.44). The combined genotypes of exon 22 C/T or T/T and intron 24 -3 c / -3 c occurred in 8.9% of patients and 0.5% of control subjects (P < 0.0001, OR 21.5,95% CI 2.91-159.6). These results suggest that defects at the SUR locus may be a major contributor to the inherited basis of NIDDM in Northern European Caucasians.
N IDDM, a common heterogeneous condition, is characterized by both impaired p-cell function and impaired insulin action (1) (2) (3) . In spite of evidence for a strong inherited component (4) , major susceptibility genes have so far not been found for the more common forms of NIDDM. Knowing that defective insulin secretion plays a major role in the disease, the genes encoding the key molecular components of the pancreatic P-cell stimulus-secretion coupling apparatus are logical candidates to be investigated.
It is now known that signals derived from the metabolism of glucose in pancreatic p-cells lead to a sequence of events that includes closure of ATP-sensitive potassium channels (IKATP); membrane depolarization; activation of voltagegated Ca 2+ channels, which results in increased intracellular Ca 2+ ; and insulin exocytosis (3, (5) (6) (7) . Sulfonylureas directly inhibit p-cell IKATP Bn^ hence lead to depolarization and insulin release (8) . Recently, the p-cell IKATP w a s shown to be a heteromultimeric structure composed of two essential subunits, the sulfonylurea receptor (SUR) (9) and a member of the small inward rectifier family, BIR (or Kir6.2 [10] ). SUR is a member of the ATP-binding cassette superfamily, and like other members, it contains two highly conserved nucleotide-binding folds (NBFs) (NBF-1 and -2, respectively). Because the BIR gene contains no detectable nucleotidebinding regions, SUR likely serves as the ATP/ADP regulatory subunit of IKATP (6)-An inherited form of neonatal hyperinsulinism (familial hyperinsulinism, OMIM [online Mendelian inheritance in man] #256450) has been shown to be associated with mutations of the NBF-2 region of the gene (11) , thus strongly implicating SUR in the physiological regulation of insulin release.
Given the central role of SUR in regulated insulin secretion, sequence variability in its gene could play a role in susceptibility to other conditions that display abnormal insulin release, such as NIDDM. We initially mapped the SUR gene on a chromosome lip 15.1 YAC (yeast artificial chromosome) contig (A. Nestorowicz, M.A.P., unpublished observations) and identified a simple sequence repeat polymorphic (SSRP) marker within 100 kb of the SUR gene. Using this polymorphic marker, we now show lack of linkage in NIDDM pedigrees and no difference in allelic frequencies between NIDDM patients and control subjects. Knowing that NIDDM is a polygenic disease, we scanned the exons comprising the two NBF regions of the SUR gene in patients with NIDDM. Two polymorphic variants were found to be GGT GTC TCT GTG CTT CC-3'  TCA CCT CCA AAC CAC CC-3'  AAC TGG CTG CCT TTC TG-3'  GGC CCC ACT CAC ATC TG-3'  GTG GGA ACT AAC TGG TG-3'  GCT CAG TAT GCC TTT CC-3'  AAC AAG CCC TGA GAA TGC-3'  TCG GGC CAA CTC TGA CC-3'  ATG ATG TGT TCC TCC TCT-3'  ACC CTC TAC TCT CTT CC-3' GAA CAG GGT CCT GTG GC-3' GCT GAG GAC AGA ACT AAG-3' CCA AGG AGG AGT GTG TC-3' TGT GAC CTC CCA CAC CT-3' CAG ACA TGA CAG GAG G-3' CTG CTC CCT CCT ACT G-3' CCA TCT GCT CCA CTC AC-3' GGC CAG ACC CCA TCC AC- 3'  TGG TAT TCC CAC CAT C-3'   5'-TGC TGG GAG TAG CAA GGG GA-3'  5'-TCT GGG GAT TGG TGC TGG GT-3'  5'-GAG TAG GTG CTC AAT AAA TGC-3'  5'-GGA GGA TGG TTA AAA GGA GATT-3'  5'-CTT CTG ACC CCA GTC CCA AG-3'  5'-GGT GAT GTG GCT CCC TTG G-3'  5'-AGT TCC TCC CCT CCA CAT CC-3'  5'-TTG GGG GTC CTG GCT TTG AA-3 -GTA TGG GCA GGG TCC GAA T-3'   167  184  228  202  110  145  200  190  156  211   249  217  258  277  235  192  254  153  230 strongly associated with the disease in Northern European Caucasians, suggesting that genetic defects at this locus may account for a significant component of the inherited basis of NIDDM in this racial group.
RESEARCH DESIGN AND METHODS
Subjects. Informed consent was obtained for all subjects before testing. The studies were approved by the University of Utah Institutional Review Board, the Central Oxford Research Ethics Committee, and the Washington University Ethics Committee. Utah subjects. The affected probands for single-strand conformation polymorphism (SSCP) screening were obtained from 35 families with a minimum of two NIDDM siblings with onset before age 65 years, as recently described (12) . To study the prevalence of the SUR gene sequence variants, 116 unrelated NIDDM patients and 110 nondiabetic unrelated control subjects of Northern European descent were recruited at the outpatient clinics of the Veteran's Affairs Medical Center and University of Utah Clinics (mean ages 63.6 ± 9.8 and 54.5 ± 13.6 years, respectively). NIDDM was diagnosed by World Health Organization criteria. Control subjects were either randomly chosen individuals or nondiabetic spouses of the affected family members, screened by a standard 75-g glucose tolerance test. U.K. subjects. Linkage analysis with the SSRP marker D11S921 was carried out on 17 NIDDM nuclear families, in which at least two siblings and one parent were affected and the other parent was normoglycemic (13) . Linkage analysis was also performed in two large maturity-onset diabetes of the young (MODY) families in whom genetic defects at other MODY loci (14-16) had been excluded. The frequency of D11S921 alleles was determined in 161 unrelated white NIDDM patients (mean age 52 years) recruited into the U.K. Prospective Diabetes Study (UKPDS) and in 55 white nondiabetic unrelated control subjects (mean age 56 years) from the same geographical areas with fasting plasma glucose <6.0 mmol/1. The prevalence of the SUR gene sequence variants was studied in 187 unrelated white NIDDM patients recruited into the UKPDS and 120 nondiabetic unrelated control subjects from the same geographical areas (17) . African-American subjects. DNA was analyzed in 122 unrelated individuals with National Diabetes Data Group NIDDM diagnostic criteria and in 87 age-and sex-matched nondiabetic subjects with no history of diabetes and a random plasma glucose <6.67 mmol/1. Clinical features of case and control groups were described previously (18) . Genotyping with the SSRP marker D11S921. Genomic DNA was prepared from leukocytes by established methods and was analyzed by polymerase chain reaction (PCR) as described (19, 20) , using D11S921 primers 5'-TGCATTCAACAAATCAACA-3' and 5'-CTTGGACCATTTA-ATCTAAAGTAAT-3'. Individuals were genotyped for the presence of each of six possible alleles, ranging in size from 243 to 255 bp. Linkage analysis in NIDDM pedigrees was performed with parameters previously obtained from segregation analysis in 59 white NIDDM nuclear pedigrees with the Pointer program (21), which excluded recessive inheritance and suggested a dominant single locus with a gene frequency of 0.013. In MODY pedigrees, previously described parameters (22) were used for linkage analysis. SSCP analysis. The primers used for exon amplification and the product sizes are shown in Table 1 . Exons were numbered from the 3' end in the order sequenced as shown in Fig. 1 . PCR products were radiolabeled by the addition of [a-
32
P]dCTP to the reaction mixture. Heat-denatured PCR products were loaded onto a 5% polyacrylamide gel and subjected to electrophoresis at 20 W for 2-4 h (25°C), for gels with 10% glycerol, or at 40 W for 1-2 h (4°C), for gels without glycerol. Variants detected by SSCP analysis were re-amplified and sequenced with a cycle sequencing kit (Perkin-Elmer/Cetus, Norwalk, CT) directly or after subcloning into a pGEM-T cloning vector (Promega, Madison, WI). Nucleotide variants were confirmed by sequencing of opposite strands and by digestion with appropriate restriction enzymes. Genotyping for variants in the SUR gene. Amplification of DNA by PCR was carried out under the same conditions as SSCP analysis except for the omission of [a-32 P]dCTP. The PCR products were digested with restriction enzymes, BsaOl (Promega), Pst 1 (Boehringer Mannheim), or Mivo I (NEB), and analyzed by either acrylamide or agarose gel electrophoresis. Genotypes were not obtained on all subjects at each locus, and the numbers evaluated are noted in the appropriate tables. Statistical analysis. Differences between groups in genotypic frequencies were assessed by Fisher's exact test and x 2 tests, with Yates' correction as needed.
RESULTS
Use of an SSRP marker at the SUR locus: linkage analysis in NIDDM and MODY families, and comparison of allele frequencies between patients and control subjects. A highly polymorphic marker, D11S921, was localized to within 100 kb of the SUR gene while constructing a physical map of the familial hyperinsulinism region on Ilpl5. 0.05. Next, allelic frequencies were compared between white NIDDM patients from the U.K. (n = 161) and unrelated control subjects (n = 55) and found not to differ (x 2 = 1.04, P = 0.79, df = 3, data not shown).
Identification of sequence variants in the two NBF
regions of the SUR gene. The distribution of mutations in a related ATP-binding cassette transporter family gene, cystic fibrosis transmembrane conductance regulator (CFTR), showed clustering in the two conserved nucleotide-binding domains in patients with cystic fibrosis (24) . Thus, the 19 exons of the SUR gene that included the two NBF regions (Fig. 1) were screened by SSCP analysis in 35 familial NIDDM probands. A total of eight sequence variants were detected. Of these, three encoded silent variants in exons 9, 19, and 26, and two encoded intronic changes that were presumed not to affect canonical splice donor or acceptor sites. Three remaining variants were considered to be of potential functional importance (Figs. 1 and 2 ).
1. A T->G change in exon 7 (NBF-2 region) resulted in a serine to alanine substitution (S1370A). Because this base change created a new Mwo I restriction site, a PCR-based restriction assay was developed that confirmed the presence of this variant.
2. A C->T change in exon 22 resulted in what was first thought to be a non-sense mutation in the NBF-1 region. This predicted non-sense mutation was based on the highly conserved amino acid sequence of the rat and hamster SUR cDNAs (9) . When the human cDNA sequence encoding exon 22 was matched, however, errors were uncovered in rat and hamster sequences that altered the reading frame. Thus, the variant in exon 22 was later found to encode an ACC_->ACI silent change (T761T). A recognition site for BsaOl is destroyed by this base change. 3. An intronic -31-»c change was located at the intron 24 splice acceptor site ( -3 tagGCC to -3 cagGCC; lowercase refers to intronic sequences). This change destroyed a Pst 1 site.
Frequencies of the SUR gene sequence variants in NIDDM patients and control subjects Exon 7 missense variant (S vs. A).
Neither the allelic nor genotypic frequencies of the exon 7 variant differed between the two groups ( Table 2 ). This amino acid polymorphism was rare in African-Americans (11 of 184 chromosomes in NIDDM cases vs. 5 of 174 in control subjects, NS).
Exon 22 variant (C vs. T).
In contrast to the results for exon 7, both the genotypic and allelic frequencies differed between NIDDM patients and control subjects for both the Utah and U.K. studies (Table 3) . Because the frequencies of the variant did not differ between Utah and U.K. subjects (Fisher's exact test, P = 0.18), combined analysis showed a highly significant difference between patients and control subjects (T allele frequency 0.07 vs. 0.02, respectively; Fisher's exact test, P = 0.0008). The OR was thus calculated to be 3.01 (95% CI 1.54-5.87). This polymorphism was very rare in an African-American population (1 of 170 chromosomes in NIDDM cases vs. 2 of 244 in nondiabetic control subjects, NS) and was not observed in Japanese subjects (n = 199; Y. Oka, personal communication) or Pima Indians (n = 35; H.I., unpublished observations).
Intron 24 splice variant (-3t vs. -3c).
The frequency of nucleotide t versus c at position -3 in the slice acceptor site of exon 24 differed between NIDDM patients and control subjects in both populations, although this difference was greater in the U.K. population (Table 4 ). The prevalence of the -3 c allele was significantly greater in the NIDDM group (0.62 vs. 0.46; Fisher's exact test, P < 0.0001; OR 1.91; 95% CI 1.50-2.44). In African-Americans, the frequency of the intron 24 -3 c allele was 0.80 in the NIDDM subjects and 0.85 in the control group (NS). Combined analysis of exon 22 and intron 24 variant genotypes and clinical characteristics. Because both the exon 22 T allele and the intron 24 -3 c allele appeared to be associated with NIDDM, we determined whether the combined presence of the two variants affected the risk for NIDDM. As shown in Table 5 , when normal subjects were evaluated by exon 22 genotypes (C/C vs. C/T or T/T), the intron 24 genotypic frequencies did not differ (x 2 = 0.79, P = 0.68). In contrast, for NIDDM subjects there was a significant difference in intron 24 genotypes when analyzed versus exon 22 genotypes (x 2 = 20.2, P < 0.0001). Comparing intron 24 genotypes between normal and NIDDM subjects with genotypes C/T or T/T at exon 22, there was a highly significant difference. The exon 22 C/T or T/T and intron 24 -3 c / -3 c genotypes were found in 28 of 314 (8.9%) NIDDM patients and 1 of 221 (0.5%) normal subjects (Fisher's exact test, P < 0.0001; OR 21.5; 95% CI 2.91-159.6).
The clinical characteristics of NIDDM subjects carrying the exon 22 T and/or the intron 24 -3 c variants, including age of onset of diabetes, fasting plasma glucose, HbA lc , and BMI, waist-to-hip ratio, plasma insulin, and f}-cell function assessed by Homeostasis Model Assessment, were found not to differ from those in NIDDM subjects without the variants (data not shown). Genotypic and n Genotype -3t/-3t -3c/-3t -3c/-3c Allele Data are n (frequency). Utah NIDDM subjects included SSCP probands. Total includes Utah and U.K. populations.
DISCUSSION
Both linkage in families and case-control analysis with a highly polymorphic marker (D11S921), located <100 kb from the SUR gene, failed to incriminate the gene in NIDDM. This linkage analysis used parameters based on models of inheritance from previous segregation analysis in NIDDM families (21) . While the results may have differed somewhat if the model parameters were altered, it is unlikely that altering these parameters would have produced dramatically different results in favor of linkage. We nevertheless hypothesized that in a polygenic disease for which the correct model of inheritance is unknown (predisposing alleles are frequent in the general population, and penetrance is strongly dependent on environmental influence), the power of these studies was unlikely to be sufficient to detect linkage, especially if a nearby genetic defect acted as a risk factor in a subset of NIDDM individuals (25, 26) . Based on these considerations and on recent evidence that SUR plays a key role in (3-cell stimulus-secretion coupling (9,10), we assessed this gene at the nucleotide level using an SSCP strategy. We identified variants in the two NBF regions in unrelated Northern European white diabetic individuals, allowing us to assess the possible contribution of this gene to the inherited susceptibility to the disease.
A common missense variant in exon 7 (SI730A) was found in approximately one-third of the chromosomes in the Northern European white populations (Table 2 ). This was predicted to disrupt a putative protein kinase A phosphorylation site in a Walker A motif of NBF-2. The serine residue is conserved in man, rat, and hamster SUR and is also present in the homologous CFTR region. While the possible consequences of this variant on the regulation of SUR function await assessment, it is unlikely that this variant constitutes a significant risk factor for NIDDM given the lack of differences between the frequencies observed in patients and control subjects.
An exon 22 variant was strongly associated with NIDDM, being present in the heterozygous condition in 13% of individuals with NIDDM compared with 5% in normal control subjects (Table 3) . Because no direct consequences can be anticipated from this third base variation, linkage disequilibrium with a functionally relevant nearby mutation is a likely mechanism to explain the association with NIDDM. Putative mutations in linkage disequilibrium with the exon 22 variant may be in the SUR gene itself or in a nearby gene. Interestingly, it is now known that the gene for BIR, the SUR cognate partner that forms the P-cell I ATP , resides in the immediate 3'-flanking region of the SUR gene (10) .
The intron 2 4 -3 t->c variant also appeared to be a marker for increased risk for NIDDM. The frequencies of the intron 24 -3 c allele were greater in NIDDM subjects than in control subjects in both the Utah and U.K. populations, and this difference was highly significant for the combined populations (Table 4) . This association was independent of the genotype at exon 22 for NIDDM subjects ( Table 5 ). The sequence variant was located at position -3 of the splice acceptor site of exon 24. For other eukaryotic genes, sequence variation at this position has been observed: 65% C, 31% T, 4% A, and 1% G (27) ; yet there is little information on the presence of a polymorphism at this -3 position. Mutations at position -3 can result in abolition of splicing of the intron in Emery Dreifus muscular dystrophy (28) ( -3 aaggag) or skipping of the exon in cystic fibrosis (27) ( -3 cag-tag). Although the frequency of the intron 2 4 -3 t-»c variant allele was high (0.46 for normal subjects), this does not exclude a possible physiological consequence. We have now performed reverse transcription-PCR analysis with primers that encompass exons 21-25 using pancreatic islet RNA from five randomly chosen individuals, and no evidence for aberrant splicing has been observed (data not shown). Thus, available evidence suggests that the intron 24 -3 c allele is likely to be in linkage disequilibrium with a nearby mutation that affects the risk of developing NIDDM.
The OR was 3.01 for the exon 22 T allele and 1.91 for the intron 24 -3 c allele. For both genotypes combined, the OR was 21.5 (95% CI 2.91-159.6). These results are consistent with the two variants being in linkage disequilibrium with separate mutations at this locus, and the presence of both predisposing variants in a compound heterozygote individual could confer increased risk for diabetes. Alternatively, both variants could be in linkage disequilibrium with each other and thus with the same putative mutation. While family analysis is necessary to unambiguously characterize haplotypes at risk, an estimate of the haplotypes can be obtained by inspection of the data in Table 5 . From those individuals with the genotypes at greatest risk for NIDDM (exon 22 C/T or T/T and intron 24 -3c/-3c, 28 NIDDM patients vs. 1 control subject), it appears that the exon 22 T/intron 24 -3 c haplotype is the one at risk for NIDDM.
It is noteworthy that within a distinct genetic locus, two single nucleotide polymorphisms were associated with NIDDM, whereas no differences in allele distribution of a flanking dinucleotide repeat marker were observed. In part, this may be explained by the assumption that the exon 22 and intron 24 variants may be closer to the putative mutation than the SSRP marker, which could be as much as 100 kb away. Furthermore, the single nucleotide sequence variation is known to be more stable than simple repeat polymorphisms (29) . This observation underscores the strength of intragenic single nucleotide markers as opposed to microsatellite markers in NIDDM population-association studies.
A potential caveat of this study design is the presence of unsuspected population stratification between NIDDM and control subjects. However, the allele distribution of the highly polymorphic SSRP marker D11S921 did not differ between case and control subjects in the U.K. group, where this marker was tested. Further, the frequency of the exon 7 missense variant did not differ between NIDDM subjects and control subjects for either the Utah or the U.K. group. Most important was the replication of almost identical results in two independently recruited populations, arguing against the existence of sampling variance as an explanation for these results.
In conclusion, our observations suggest that defects either at or near the SUR locus contribute to the inherited basis of the common form of NIDDM. Studies necessary to confirm these findings include replication in independent populations, intrafamily-association studies (30) , and further characterization of the SUR gene and flanking genes to identify mutations.
